Zhe et al. reported that in the Non-Small Cell Lung Cancer (NSCLC) A549 cell model, baicalein inhibits the RhoA/ROCK signaling pathway in a dose-dependent manner, disrupts the cytoskeletal F-actin network, downregulates the expression of VM-related factors including VE-cadherin, EphA2, MMP2/9/14, PI3K, and LAMC2, and blocks the interaction between tumor cells and the ECM, thereby suppressing the formation of VM tubular structures (Zhang et al., 2020). This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.